Animal Study: Mitragynine Reduces Alcohol Self-Administration in Rats, Enhanced by Naltrexone Combination

Why it matters

Kratom alkaloid mitragynine may have therapeutic potential for alcohol use disorder, particularly in combination with naltrexone. This preclinical evidence informs future clinical trials exploring multi-target approaches for AUD.

The big picture

Alcohol use disorder affects millions globally with limited FDA-approved pharmacotherapies. Mitragynine is used by some individuals to reduce opioid withdrawal, and has shown effects on alcohol consumption in animal models. This study directly tested mitragynine alone and combined with naltrexone on alcohol self-administration.

Key findings

• Both mitragynine and naltrexone reduced alcohol self-administration in female rats; combination treatment was more effective than either drug alone; neither drug depressed locomotor activity, ruling out non-specific sedation; combined treatment enhanced neural activity (cFos expression) in reward-related brain regions more than either agent alone

What they say

Researchers concluded: "MG decreased alcohol reinforcement more than NTX but the combination of the two was more impactful than either alone and engendered no adverse effects suggesting decreases in alcohol self-administration were not due to non-specific depression of activity levels."

Bottom line

**Mitragynine shows promise for reducing alcohol reinforcement; combination with naltrexone produces synergistic effects without depressing general activity—suggesting therapeutic potential for alcohol use disorder.**